APA (7th ed.) Citation

A, D., RD, H., RD, C., O, H., SJ, K., JSW, K., . . . R, W. (2021). LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: Phase 1 dose-escalation trial. Investigational new drugs, 39(4), 1057. https://doi.org/10.1007/s10637-021-01084-8

Chicago Style (17th ed.) Citation

A, Dowlati, et al. "LY3022855, an Anti-colony Stimulating Factor-1 Receptor (CSF-1R) Monoclonal Antibody, in Patients with Advanced Solid Tumors Refractory to Standard Therapy: Phase 1 Dose-escalation Trial." Investigational New Drugs 39, no. 4 (2021): 1057. https://doi.org/10.1007/s10637-021-01084-8.

MLA (9th ed.) Citation

A, Dowlati, et al. "LY3022855, an Anti-colony Stimulating Factor-1 Receptor (CSF-1R) Monoclonal Antibody, in Patients with Advanced Solid Tumors Refractory to Standard Therapy: Phase 1 Dose-escalation Trial." Investigational New Drugs, vol. 39, no. 4, 2021, p. 1057, https://doi.org/10.1007/s10637-021-01084-8.